R Bedimo1, R Ghurani, M Nsuami, D Turner, M-B Kvanli, G Brown, D Margolis. 1. Department of Medicine, Division of Infectious Diseases, University of Texas South-Western Medical Center at Dallas, Dallas, TX 75216, USA. roger.bedimo@med.va.gov
Abstract
BACKGROUND: Among HIV-infected patients, hepatitis C virus (HCV) coinfection is associated with increased rates of lipodystrophy and insulin resistance. Its impact on HIV-associated dyslipidaemia is less clear. METHODS: The lipid profiles of all HIV-infected patients and a subset of HCV-infected patients seen at the VA Medical Center in Dallas from January 2003 to March 2004 were analysed. Demographic data, HCV serostatus, and HIV treatment history were recorded. Lipid profiles of HIV/HCV-coinfected patients were compared with those of HIV-monoinfected and HCV-monoinfected patients. RESULTS: A total of 359 HIV-infected patients, 91 (25.3%) of whom were HCV coinfected, and 112 HCV-infected patients were included in the analysis. Among the HIV-infected patients, HCV coinfection was associated with a reduced risk of hypercholesterolaemia [9.9% vs 24.8%; relative risk (RR)=0.333; 95% confidence interval (CI)=0.158-0.699; P<0.001] and hypertriglyceridaemia (48.4% vs 60.3%; RR=0.616; 95% CI=0.382-0.994; P=0.031). After controlling for duration of protease inhibitor (PI) therapy, race, alanine aminotransferase (ALT) concentration and platelet count, HCV remained an independent predictor of hypercholesterolaemia (RR=0.369; P=0.01) and any dyslipidaemia (RR=0.531; P=0.019). In addition, the rate of dyslipidaemias was lower among HCV-monoinfected than HIV/HCV-coinfected patients (29.5% vs 50.5; P=0.002). White race was also an independent predictor of dyslipidaemia (73.8% vs 50.7%; RR=2.32; 95% CI=1.44-3.76; P=0.001). CONCLUSIONS: HCV coinfection independently predicted lower rates of dyslipidaemia among HIV-infected patients. An analysis of lipid kinetics among mono- and coinfected patients may elucidate the mechanisms of the apparent protective effect of HCV infection.
BACKGROUND: Among HIV-infectedpatients, hepatitis C virus (HCV) coinfection is associated with increased rates of lipodystrophy and insulin resistance. Its impact on HIV-associated dyslipidaemia is less clear. METHODS: The lipid profiles of all HIV-infectedpatients and a subset of HCV-infectedpatients seen at the VA Medical Center in Dallas from January 2003 to March 2004 were analysed. Demographic data, HCV serostatus, and HIV treatment history were recorded. Lipid profiles of HIV/HCV-coinfectedpatients were compared with those of HIV-monoinfected and HCV-monoinfected patients. RESULTS: A total of 359 HIV-infectedpatients, 91 (25.3%) of whom were HCV coinfected, and 112 HCV-infectedpatients were included in the analysis. Among the HIV-infectedpatients, HCV coinfection was associated with a reduced risk of hypercholesterolaemia [9.9% vs 24.8%; relative risk (RR)=0.333; 95% confidence interval (CI)=0.158-0.699; P<0.001] and hypertriglyceridaemia (48.4% vs 60.3%; RR=0.616; 95% CI=0.382-0.994; P=0.031). After controlling for duration of protease inhibitor (PI) therapy, race, alanine aminotransferase (ALT) concentration and platelet count, HCV remained an independent predictor of hypercholesterolaemia (RR=0.369; P=0.01) and any dyslipidaemia (RR=0.531; P=0.019). In addition, the rate of dyslipidaemias was lower among HCV-monoinfected than HIV/HCV-coinfectedpatients (29.5% vs 50.5; P=0.002). White race was also an independent predictor of dyslipidaemia (73.8% vs 50.7%; RR=2.32; 95% CI=1.44-3.76; P=0.001). CONCLUSIONS:HCV coinfection independently predicted lower rates of dyslipidaemia among HIV-infectedpatients. An analysis of lipid kinetics among mono- and coinfected patients may elucidate the mechanisms of the apparent protective effect of HCV infection.
Authors: Josephine H Li; Xiang Qian Lao; Hans L Tillmann; Jennifer Rowell; Keyur Patel; Alexander Thompson; Sunil Suchindran; Andrew J Muir; John R Guyton; Stephen D Gardner; John G McHutchison; Jeanette J McCarthy Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Heidi M Crane; Carl Grunfeld; James H Willig; Michael J Mugavero; Stephen Van Rompaey; Richard Moore; Benigno Rodriguez; Betsy J Feldman; Michael M Lederman; Michael S Saag; Mari M Kitahata Journal: AIDS Date: 2011-01-14 Impact factor: 4.177
Authors: Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel Journal: AIDS Res Hum Retroviruses Date: 2018-11-27 Impact factor: 2.205
Authors: Kerry Townsend; Eric G Meissner; Sreetha Sidharthan; Maureen Sampson; Alan T Remaley; Lydia Tang; Anita Kohli; Anu Osinusi; Henry Masur; Shyam Kottilil Journal: AIDS Res Hum Retroviruses Date: 2015-12-15 Impact factor: 2.205
Authors: José R Santos; José Moltó; Josep M Llibre; Eugenia Negredo; Isabel Bravo; Arelly Ornelas; Bonaventura Clotet; Roger Paredes Journal: PLoS One Date: 2012-05-29 Impact factor: 3.240